These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14715864)

  • 1. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
    Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O
    J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
    Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
    Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
    Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
    Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of overnight restoration of euglycemia on glucose effectiveness in type 2 diabetes mellitus.
    Basu R; Basu A; Nielsen M; Shah P; Rizza RA
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2314-9. PubMed ID: 10404795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans.
    Gosmanov NR; Szoke E; Israelian Z; Smith T; Cryer PE; Gerich JE; Meyer C
    Diabetes Care; 2005 May; 28(5):1124-31. PubMed ID: 15855577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
    Manzella D; Grella R; Abbatecola AM; Paolisso G
    Diabetes Care; 2005 Feb; 28(2):366-71. PubMed ID: 15677794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
    Landstedt-Hallin L; Adamson U; Lins PE
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3140-5. PubMed ID: 10487677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
    Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
    Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
    Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
    Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive.
    Veldhuis JD; Anderson SM; Patrie JT; Bowers CY
    J Clin Endocrinol Metab; 2004 Jan; 89(1):121-7. PubMed ID: 14715838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.